stockrow
Friday 6 November 2026
Export ZOMDF’s income statement to Excel — free account
Zomedica Corp.
ZOMDF Healthcare Medical Devices
Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024.
- Revenue
- +22.3%
- EPS
- +48.4%
- Free cash flow
- +32.5%
Quarter to September 2026, against a year earlier
0.09
0.00
0.00%
Follow ZOMDF
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.03 | 2.66 | 3.43 | 3.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(28.31) | (38.41) | (22.37) | (109.00) | |
P/B ratio |
0.75 | 0.91 | 1.06 | 0.85 | |
Price to Tangible BV |
1.17 | 1.40 | 1.61 | 1.28 | |
EV/Sales |
1.00 | 1.47 | 2.06 | 1.41 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.38) | (4.07) | (4.34) | (2.56) | |
EV/FCF |
(2.88) | (3.62) | (4.08) | (2.43) | |
Quick Ratio |
5.20 | 5.57 | 6.11 | 6.00 | |
Current Ratio |
6.09 | 6.43 | 7.01 | 6.78 | |
Net Debt/EBITDA |
0.00 | 19.06 | 15.26 | 15.88 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.31 | 0.29 | 0.26 | 0.19 | |
Operating CF/Net income |
0.87 | 0.68 | 1.16 | 0.20 | |
Capex/Depreciation |
0.00 | (0.46) | (0.29) | (0.10) | |
Research and Development Expense of Revenue |
12.16% | 11.25% | 13.12% | 15.69% | |
Selling, General and Administrative Expense of Revenue |
83.49% | 95.19% | 104.90% | 102.10% | |
Intangible Assets out of Total Assets |
0.00 | 0.32 | 0.31 | 0.31 | |
Share Based Compensation of Revenue |
(0.38%) | 0.73% | 7.31% | 6.94% | |
Graham Net Nets |
0.57 | 0.48 | 0.42 | 0.53 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(20.25%) | (19.20%) | (19.08%) | (88.30%) | |
Free Cash Flow Yield |
(17.18%) | (15.33%) | (14.73%) | (18.98%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Cash per Share |
0.04 | 0.05 | 0.05 | 0.05 | |
Shareholders Equity per Share |
0.11 | 0.11 | 0.11 | 0.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.11 | 0.11 | 0.11 | 0.12 | |
Free Cash Flow |
(3.24) | (3.37) | (5.77) | (1.09) | |
Working Capital |
46.34 | 48.89 | 51.47 | 54.59 | |
Capital Expenditures |
(0.47) | (0.82) | (0.51) | (0.19) | |
Net Current Asset Value |
44.70 | 47.03 | 49.44 | 52.40 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.09 | 0.06 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.40 | 4.47 | 3.46 | 3.26 | |
Average Payables |
1.87 | 1.82 | 2.25 | 1.82 | |
Average Inventory |
5.65 | 5.86 | 5.62 | 5.30 | |
Average Assets |
122.97 | 127.31 | 132.26 | 167.20 | |
Average Common Equity |
111.99 | 116.32 | 121.69 | 155.53 |
Columns are period end dates · fundamentals updated 4 Nov 2026